EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice

Alba Sanz-González iD, Irene Cózar-Castellano iD, Christophe Broca iD, Julia Sabatier iD, Gerardo A Acosta iD, Miriam Royo iD, Carla Hernándo-Muñoz iD, Tomás Torroba iD, Germán Perdomo iD, Beatriz Merino iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Alba Sanz-González und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Excelencia Instituto de Biomedicina y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC) y Universidad de Va…. Hauptthemen laut MEDLINE: Insulysin, Diabetes Mellitus, Type 2, Insulin-Secreting Cells, Islets of Langerhans. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, European Foundation for the Study of Diabetes, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the use of synthetic preimplantation factor (sPIF) as a potential therapeutic tool for improving glucose‐stimulated insulin secretion (GSIS), glucose tolerance and insulin sensitivity in the setting of diabetes. Materials and Methods We used a preclinical murine model of type 2 diabetes (T2D) induced by high‐fat diet (HFD) feeding for 12 weeks. Saline or sPIF (1 mg/kg/day) was administered to mice by subcutaneously implanted osmotic mini‐pumps for 25 days. Glucose tolerance, circulating insulin and C‐peptide levels, and GSIS were assessed. In addition, β‐cells (Min‐6) were used to test the effects of sPIF on GSIS and insulin‐degrading enzyme (IDE) activity in vitro. The effect of sPIF on GSIS was also tested in human islets.

Results

GSIS was enhanced 2‐fold by sPIF in human islets ex vivo. Furthermore, continuous administration of sPIF to HFD mice increased circulating levels of insulin and improved glucose tolerance, independently of hepatic insulin clearance. Of note, islets isolated from mice treated with sPIF exhibited restored β‐cell function. Finally, genetic (shRNA‐IDE) or pharmacological (6bK) inactivation of IDE in Min‐6 abolished sPIF‐mediated effects on GSIS, showing that both the protein and its protease activity are required for its action.

Conclusions

We conclude that sPIF is a promising secretagogue for the treatment of T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulysinDiabetes Mellitus, Type 2Insulin-Secreting CellsIslets of LangerhansMiceHumansAnimalsInsulin SecretionMice, ObeseGlucoseInsulinDiet, High-Fat

Stichwörter der Autor:innen

antidiabetic drugbeta cell functiondrug mechanisminsulin secretagogueinsulin secretion

Substanzen

InsulysinGlucoseInsulin

Autor:innen und Institutionen

  • Unidad de Excelencia Instituto de Biomedicina y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC) y Universidad de Valladolid (UVa), Valladolid, Spain.
  • Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain.
  • Laboratory of Cell Therapy for Diabetes (LTCDPRIMS), IRMB Hop. St Eloi, CHU Montpellier, Montpellier, France.
  • Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), Barcelona, Spain.
  • Department of Surfactants and Nanobiotechnology, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain.
  • Department of Organic Chemistry, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Alba Sanz-González, Irene Cózar-Castellano, Christophe Broca, Julia Sabatier, Gerardo A Acosta, Miriam Royo, Carla Hernándo-Muñoz, Tomás Torroba, Germán Perdomo, Beatriz Merino

Förderung

  • Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina
  • European Foundation for the Study of Diabetes
  • Generalitat de Catalunya
  • Junta de Castilla y León
  • Sociedad Española de Diabetes

Zitieren

APA

Sanz-González, A., Cózar-Castellano, I., Broca, C., Sabatier, J., Acosta, G. A., Royo, M., Hernándo-Muñoz, C., Torroba, T., Perdomo, G., & Merino, B. (2023). Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15225

Vancouver

Sanz-González A, Cózar-Castellano I, Broca C, Sabatier J, Acosta GA, Royo M, et al. Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15225

BibTeX
@article{SanzGonzlez2023,
  author = {Sanz-González, Alba and Cózar-Castellano, Irene and Broca, Christophe and Sabatier, Julia and Acosta, Gerardo A and Royo, Miriam and Hernándo-Muñoz, Carla and Torroba, Tomás and Perdomo, Germán and Merino, Beatriz},
  title = {Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15225}
}
Kostenlos starten →